Harrow Health (NASDAQ:HROW) updated its first quarter 2021 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of – for the period. The company issued revenue guidance of $14.90 million-$15.50 million, compared to the consensus revenue estimate of $13.66 million.
A number of equities research analysts have weighed in on the stock. B. Riley upped their price objective on shares of Harrow Health from $12.00 to $14.00 and gave the stock a buy rating in a report on Monday, January 4th. Zacks Investment Research cut shares of Harrow Health from a buy rating to a sell rating in a report on Wednesday, April 21st.
Shares of NASDAQ:HROW traded down $0.28 during trading on Tuesday, reaching $7.47. 169,852 shares of the stock traded hands, compared to its average volume of 221,089. The stock has a 50-day moving average of $7.34 and a two-hundred day moving average of $7.08. Harrow Health has a 52-week low of $3.63 and a 52-week high of $11.10. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.68 and a current ratio of 2.97. The stock has a market cap of $194.10 million, a P/E ratio of -96.88 and a beta of 1.08.
About Harrow Health
Harrow Health, Inc engages in the development, production, and sale of innovative medications. It operates through the Pharmaceutical Compounding and Pharmaceutical Drug Development segments. The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L.
Recommended Story: Stocks Increasing Dividends
Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.